ArticleCancers2022
The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Associations of CT-Derived Skeletal Muscle Index and Density With Postoperative Outcomes Following Colorectal Cancer Surgery.Journal of cachexia, sarcopenia and muscle · 2026Article
- Fully automated CT-based quantitative body composition analysis for predicting survival in patients with HCC undergoing TACE: a dual-cohort study.Scientific reports · 2026Article
- Quality and Quantity? The Clinical Significance of Myosteatosis in Various Liver Diseases: A Narrative Review.Journal of clinical and translational hepatology · 2025Review
- Assessing SARCopenia with ecHOgraphy in Community-Dwelling Older Adults: A Validation Study (SARCHO).Journal of frailty, sarcopenia and falls · 2025Article
- Article
- Preoperative myosteatosis as a novel prognostic biomarker after anatomical lung resection for non-small cell lung cancer.Surgery today · 2025Article
- New research progress of sarcopenia in surgically resectable malignant tumor diseases.World journal of clinical oncology · 2025Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Impacts Long-Term Outcomes After Curative-Intent Surgery for Hepatocellular Carcinoma.Alimentary pharmacology & therapeutics · 2025Article
- Review
- Prognostic Value of Myosteatosis and Creatinine-to-Cystatin C Ratio in Patients with Pancreatic Cancer Who Underwent Radical Surgery.Annals of surgical oncology · 2024Article
- Review
- Article
- Development and validation of a clinical factors and body fat distribution-based nomogram to predict refractoriness of transarterial chemoembolization in hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2024Article
- The coexistence of myosteatosis and the creatinine/cystatin C ratio are determinants of outcomes in cholangiocarcinoma patients undergoing curative surgery.Frontiers in oncology · 2024Article
- A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients.Biomarker research · 2023Article
- E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy.The British journal of surgery · 2023Article
- Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis.Oncology letters · 2023Article
- Article
- Role of Machine Learning-Based CT Body Composition in Risk Prediction and Prognostication: Current State and Future Directions.Diagnostics (Basel, Switzerland) · 2023Review
- Myosteatosis Is Not Associated with Complications or Survival in HCC Patients Undergoing Trans Arterial Embolization.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Alterations of body composition, especially decreased muscle mass (sarcopenia) and impaired muscle quality (myosteatosis), are associated with inferior outcomes in various clinical conditions. The data of 100 consecutive patients who underwent partial hepatectomy for hepatocellular carcinoma (HCC) at a German university medical centre were retrospectively analysed (May 2008-December 2019). Myosteatosis and sarcopenia were evaluated using preoperative computed-tomography-based segmentation. We investigated the predictive role of alterations in body composition on perioperative morbidity, mortality and long-term oncological outcome. Myosteatotic patients were significantly inferior in terms of major postoperative complications (Clavien-Dindo ≥ 3b; 25% vs. 5%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.